BIOMICTRA® is widely used to treat C. difficile infections in clinical settings.
As Australia’s first regulated Class 2 donor-derived microbiome therapy listed on the ARTG, BiomeBank guarantees stringent multi-stage donor screening and expert nationwide support throughout the process.
Donor derived Faecal Microbiota Transplantation (FMT) is a highly effective therapy for the treatment of recurrent Clostridioides difficile infection — the most common cause of healthcare associated diarrhoea. Multiple randomised controlled trials and meta-analyses of these studies have demonstrated the superiority of FMT over antibiotic therapy alone for the treatment of recurrent C.difficile infection.
While FMT is now the standard of care for recurrent C. difficile infection in most international guidelines, evidence is emerging for its use in other diseases.
BiomeBank’s co-founders Associate Professor Sam Costello and Professor Rob Bryant have been pioneers in this field and BiomeBank is facilitating a number of clinical trials in a range of diseases with collaborating organisations.
Current Treatment (Antibiotics) vs Faecal Microbial Transplantation (FMT)
BB265 is a rationally designed cultured microbiome therapy engineered for the treatment of ulcerative colitis. BB265 was developed using BiomeBank’s CONSORTIOME® platform and data from a discovery trial using BIOMICTRA® (donor derived) therapy in patients with active ulcerative colitis. BB265 is now scheduled to enter a phase 1b/2a study.
BB128 is a rationally designed cultured microbiome therapy engineered for the treatment of an orphan disease indication. A discovery trial in this orphan disease indication is underway using BIOMICTRA®